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Summary The product of Nm23 gene has been proposed as a candidate tumour metastasis suppressor
protein. A strong association has been observed between reduced expression of Nm23 gene and acquisition of
metastatic behaviour in some tumour cells including breast cancer and melanoma, but not in others such as
colon cancer, neuroblastoma, and cervical cancer. In the present study, we examined the abundance of Nm23
mRNA in 39 thyroid tissue specimens including five multinodular goitres, one follicular adenoma, 26 papillary
and three follicular carcinomas, and four anaplastic carcinomas. Nm23 was found to be expressed in all the
tissue specimens. The expression was, however, variable in different stages of thyroid carcinoma. In stages I
through III of differentiated thyroid carcinoma, the average level of Nm23 gene expression was comparable to
that in multinodular goitres. In advanced stage of thyroid carcinoma (stage IV and anaplastic), 2-fold increase
ofNm23 expression was noted. No mutations were found in the coding region of the gene. Nm23 mRNA level
cannot, therefore, be used as a marker of low metastatic potential in thyroid carcinomas. The association of
high level Nm23 expression with anaplastic thyroid carcinoma suggests its correlation with rapid cell
proliferation.
The protein product of Nm23 gene has recently been pro-
posed to play an important role in tumour metastasis
suppression (Rosengard et al., 1989; Steeg et al., 1989). The
Nm23 protein has substantial homology with the protein
encoded by a Drosophila abnormal wing discs (awd) deve-
lopmental gene, and nucleoside diphosphate (NDP) kinase,
which catalyses the phosphorylation of nucleoside diphos-
phate into nucleoside triphosphates (Biggs, et al., 1990;
Kimura et al., 1990; Wallet et al., 1990). The abundance of
Nm23 expression was described to be inversely correlate with
metastatic potential in several rodent metastasis model
systems: murine k-1735 melanomas (Steeg et al., 1988; Leone
et al., 1991), N-nitrosomethylurea-induced rat mammary
tumours (Steeg et al., 1988), mouse mammary tumour virus-
induced tumours (Steeg et al., 1989) and cotransfected with
ras alone or ras plus adenovirus 2E1A rat embryo fibroblasts
(Steeg et al., 1988). The expression of human Nm23 gene was
also found to be lower in human breast cancer with high
metastatic potential than in that with low metastatic poten-
tial (Bevilacqua et al., 1989; Barnes et al., 1991; Hennessy et
al., 1991; Hirayama et al., 1991). Such a correlation was,
however, not observed in some other human tumours such as
colon cancer (Haut et al., 1991), neuroblastoma (Hailat et al.,
1991), and some solid tumours (Lacombe et al., 1991). The
expression of the gene was equally increased in both high and
low metastatic colon cancers. In neuroblastoma and some
solid tumours Nm23 expression was positively associated
with advanced disease stage.
Thyroid carcinoma of follicular origin is one of the most
common cancers affecting endocrine tissues. It spans a wide
range of biologic behaviour with broadly differing prognoses.
In general, differentiated (papillary and follicular) carcinomas
grow less aggressively and have a relatively good prognosis,
whereas poorly differentiated (anaplastic) carcinomas are
very aggressive and most patients die within a year of its
diagnosis. The disease course is, however, extremely variable.
It is well known that thyroid carcinomas of similar histology
can behave divergently in terms of local invasions and distant
metastases. Currently there is no reliable way to predict the
disease course with confidence. In the present study we
examined Nm23 gene expression among different types of
thyroid carcinomas to find whether its abundance associated
with tumour metastatic behaviour and progression.
Materials and methods
All tumours were obtained at surgery from King Faisal
Specialist Hospital and Research Centre in Saudi Arabia.
Tissues were immediately frozen in liquid nitrogen and stored
at - 70'C until processed. The clinical staging was based on
the TNM classification of thyroid carcinoma (DeGroot &
Sridama, 1989), stage I: intrathyroidal involvement only,
stage II: regional lymph node involvement, stage III: adjacent
tissue invasion, and stage IV: distant metastasis. Five multi-
nodular goitres (adenomatous hyperplasia), one follicular
adenoma, 26 papillary carcinomas, three follicular carcin-
omas and four anaplastic carcinomas were studied.
Full-length human Nm23-H1 cDNA probe was kindly
donated by Dr Patricia Steeg of National Cancer Institute,
Bethesda, Maryland, USA.
The oligonucleotide probe for 18S ribosomal RNA was
synthesised and the sequence is as follows: 5'-GGTCAGCG-
CTCGTCGGCATGTAATAG-3'.
RNA extraction and Northern hybridisation
Total RNA was extracted by the guanidinium thiocyanate-
phenol-chloroform method (Chomczynski et al., 1987).
Twenty ;Lg of total RNA was fractionated on 1% agarose gel
containing 2.2 M formaldehyde and blotted onto nylon mem-
branes (Hybond-N, Amersham) by capillary transfer. The
accuracy of RNA loading was monitored by ethidium
bromide staining and later by hybridisation to an oligoprobe
for 18S ribosomal RNA as previously described (Shi et al.,
1991). The Nm23-H1 cDNA probe was labelled with [a-32P]-
dCTP to a specific activity of I09 c.p.m. Lg-' using Phar-
macia's random primer labelling kit. Hybridisation was
performed at 42°C for 18 h in 6 x SSPE, 10 mM EDTA,
5xDenhardt's solution, 0.5% SDS, 100l gml-' denatured
salmon testis DNA and 50% formamide. The membranes
were then washed twice in 2 x SSPE at 65'C and exposed to
Kodak XAR-5 film at - 70'C with intensifying screens.
Following autoradiography band intensities were quanti-
tated by a Bio-Rad scanning laser densitometry and normal-
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between specimen groups was done using the unpaired
Student's t-test.
PCR-SSCP analysis
Five ,sg of total RNA was reverse transcribed into cDNA in
15 LI volume, using Pharmacia's first-strand cDNA synthesis
kit. Four PCR primers were synthesised, two of which
(primer 1 and 4) flanked the coding region of the Nm23-HI
gene and the other two (primer 2 and 3) were from the
middle of the coding region. Primers 1 and 2 (5'-CAGCCG-
GAGTTCAAACCTAA-3', 5'-TTGGTCTCCCCGAGCATG-
ACT-3'), and Primers 3 and 4 (5'-GGGCTGAATGTGGTG-
AAGACG-3', 5'-GGATGTGAAAAGCAATGTGG-3') were
used to generate by PCR two overlapping fragments, each
about 350 bp. 0.5 tl of tumour cDNA was used for PCR in
25 LIl of buffer containing 0.2tLM primers end-labelled with
[y]-32P]ATP. Samples were denatured at 94°C for 3 min and
submitted to 25 cycles of amplification under the following
conditions: 40 s denaturation at 94C, 40 s annealing at 56°C,
and 40 s extension at 72C.
Single-strand conformation polymorphism analysis was
done as described previously (Orita et al., 1989a,b). Briefly,
1 tlI of each amplified product was diluted in 20 jlI loading
buffer containing 95% formamide, 20 mM EDTA, 0.05%
bromophenol blue and 0.05% xylene cyanol, and heated at
95°C for 3 min. Two yI was loaded into 5% non-denaturing
polyacrylamide gel with 10% glycerol and run at room
temperature, 30 watts for 6 h. The gel was then exposed to
Kodak XAR-5 film overnight at - 70°C.
DNA sequencing analysis
DNA sequencing was performed by the dideoxy chain ter-
mination method after cloning the PCR products into TA
cloning vector (Invitrogen Co., CA, USA).
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Figure 2 Nm23 expression in thyroid tumours. The levels of
Nm23 mRNA were quantitated densitometrically from Northern
blots and blotted against multinodular goitres and thyroid
tumours with different histologic types and clinical stages. The
only follicular adenoma specimen was grouped with multinodular
goitres. The levels of 18S ribosomal RNA were used as an
internal standard to correct variations in the amount of RNA
loaded. Means and standard errors of the mean are indicated
adjacent to the dot plots.
Results
The abundance of Nm23 mRNA was examined in tissues
from five multinodular goitres and 34 thyroid tumours.
Nm23 was expressed in all the thyroid tissue specimens. The
expression level was, however, variable in different stages of
thyroid carcinoma. Figure 1 shows a representative Northern
blot hybridisation. The expression level of Nm23 gene was
quantitated by laser densitometry and compared with
different stages of thyroid carcinoma. As shown in Figure 2,
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Figure 1 Northern blot hybridisation of Nm23 gene expression in 14 thyroid specimens. Total RNA was electrophoresed on
agarose/formaldehyde gel and blotted onto a nylon membrane. Hybridisation was carried out with a full-length Nm23-Hl cDNA
probe (upper panel), and an oligoprobe for 18S ribosomal RNA to monitor RNA loading (lower panel). PC: papillary carcinoma;
AC: anaplastic carcinoma; Goitre: multinodular goitre; Roman numerals stand for different disease stages.Nm23 GENE EXPRESSION IN THYROID CANCER 387
multinodular goitres have a value of 5.15 ± 0.53 (mean +
SEM); Stage I carcinomas, 6.74 + 1.30; Stage II carcinomas,
5.61 ± 0.47; Stage III carcinomas, 5.16 ± 0.76; Stage IV car-
cinomas, 9.23 + 1.30; Anaplastic carcinomas, 12.85 ± 1.55.
Therefore, in early stages of differentiated thyroid carcinoma
(stage I and II), Nm23 expression was comparable to that in
multinodular goitres. In stage III thyroid carcinomas, Nm23
mRNA was reduced in 50% of specimens. The average level
at this stage was, however, not reduced (Figure 2). Surpris-
ingly, in advanced stages ofthyroid carcinomas (stage IV and
anaplastic), Nm23 gene expression was significantly increased
(P<0.01, unpaired t-test) (Figures 1 & 2). The tumour speci-
mens were reviewed by an independent pathologist. There
was no clear correlation of Nm23 expression with the pro-
portion of stromal tissues present in the tumour samples. It
is, therefore, unlikely that stromal tissues contributed
significantly to the high intra-group variation of Nm23 ex-
pression.
The wide variation of Nm23 gene expression in different
stage thyroid tumours may have resulted from mutations or
deletions in the coding region of the gene. To rule out such a
possibility, we screened for Nm23-HI gene mutations in these
thyroid tumour specimens by RT-PCR-SSCP technique.
Primers 1 and 4 were used to specifically amplify Nm23-Hl
coding sequence. No mutations were found although we did
find p53 mutations in nine of these tumour specimens using
the same cDNA mix and technique. Four cDNA samples
generated by PCR were randomly chosen and the coding
region was sequenced. Two of them were from anaplastic
carcinoma specimens which had high level Nm23 expression,
whereas the other two were from papillary carcinoma speci-
mens which had reduced Nm23 expression. None of the
specimens sequenced was found to have mutations.
Discussion
The data presented herein demonstrate that Nm23 was ex-
pressed in both benign and malignant thyroid lesions. By
contrast to the findings reported in some tumours such as
breast cancer (Bevilacqua et al., 1989; Barnes et al., 1991;
Hennessy et al., 1991; Hirayama et al., 1991) and melanoma
(Steeg et al., 1988; Leone et al., 1991) that high metastatic
potential correlates with lower Nm23 expression, our results
show that the expression of Nm23 is further increased in
advanced stage of thyroid carcinomas. The mechanism for
this increase and its effect on the tumour progression is not
clear. It is likely that in certain tumours such as neuroblas-
toma (Hailat et al., 1991), colon cancer (Haut et al., 1991)
and thyroid tumour (this study), Nm23 expression reflects
cell proliferation. This conclusion is supported by recent
study showing Nm23-Hl expression is related to cell pro-
liferation (Keim et al., 1992) and our unpublished observa-
tion that Nm23 was expressed at higher levels in the early
stage as compared to the late stage of mouse embryogene-
sis.
It is known that Nm23 gene product has NDP kinase
activity which provides intracellular pools of nucleoside tri-
phosphates (excluding ATP) required for nucleic acid syn-
thesis (Liotta & Steeg, 1990; Gilles et al., 1991). In many
systems, NDP kinases have been found associated with GTP
binding proteins including elongation factor (Walton & Gill,
1975; Ohtsuki & Yokoyama, 1987), microtubules (Nickerson
& Wells, 1984) and p21 (Ohtsuki et al., 1986) or Gsa
(Kimura & Shimada, 1988; Otero, 1990), suggesting that they
are involved in processes like protein synthesis, tubulin poly-
merisation in the mitotic spindle and cytoskeleton, and signal
transduction by supplying GTP to GTP binding proteins.
Thus a high level Nm23 expression could possibly induce
pleiotropic effects on cellular functions.
A second human Nm23 gene (Nm23-H2) has been dis-
covered recently. It encodes a protein with a predicted
Mr= 17,000 and is 88% identical to the Nm23-Hl protein
sequence (Stahl et al., 1991). The Nm23-H1 probe we used
does not efficiently distinguish between the two Nm23
mRNAs. Northern blot hybridisation of Nm23-H2-specific
probe to breast tumours and cell lines shows that Nm23-H2
expression was also reduced in high metastatic potential
tumour cells but to a less extent than Nm23-Hl (Stahl et al.,
1991), indicating that the two genes are regulated independ-
ently. It is thus possible that the observed Nm23 expression
in thyroid tumours could be one of several distinct forms of
Nm23 that are variably expressed in different cell types and
that could play different roles.
Somatic allelic deletions of Nm23-H1 (including homozy-
gous deletions in colon cancer) have been reported in human
cancers such as breast, kidney, colon and lung (Cohn et al.,
1991; Leone et al., 1991). Cohn et al. (1991) demonstrated
that 73% patients with Nm23-HI deletions in colon cancer
had distant metastases as compared to 20% without Nm23-
HI deletions, supporting its anti-metastatic role in colon
cancers. Their studies seem to contradict the report by Haut
et al., who found that Nm23 mRNA levels were higher in
invasive colon cancers (Haut et al., 1991). Further studies are
required to prove that the increased Nm23 product is not
mutant forms. In our study, we have shown that no muta-
tions were detected in the coding region of Nm23-H1 by
SSCP technique. However, we cannot completely exclude the
possibility of mutation, especially in the regulatory region of
Nm23-H1. Moreover, we do not yet know whether allelic
deletions of Nm23-HI or mutations of Nm23-H2 exist in
thyroid tumours.
In summary, Nm23 is expressed in both benign and malig-
nant thyroid lesions. No correlation could be demonstrated
between high level Nm23 expression and its anti-metastatic
potential. Therefore, Nm23 mRNA level cannot be used as a
marker of low metastatic potential in thyroid carcinomas.
The high level Nm23 expression in advanced thyroid carcin-
oma suggests that it may be participated in cell proliferation.
Tissue-specific factors may be involved in the dissociation of
Nm23 expression from its anti-metastatic activity.
We wish to thank Dr Patricia Steeg for the generous gift of Nm23
cDNA, and Drs A.M. Aktar, M. Ali, S. Ingemansson, S.S. Hussain
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